A 30-year-old male diagnosed three years previously with reversible cerebral vasoconstriction syndrome (RCVS) presented to the department of neurology with an accumulation of attacks mimicking previous RCVS attacks and fulfilling the diagnostic criteria for RCVS after receiving the first Pfizer COVID-19 vaccine. The neurologic exam, blood samples, electrocardiogram (ECG), and computer tomography of the head (CTC) were normal. The patient was treated with the angiotensin 2 receptor antagonist, losartan, with a good response and was discharged with a prescription for losartan lasting until three days after the second Pfizer COVID-19 vaccine. No further RCVS attacks were reported. These findings indicate that the COVID-19 vaccine might induce RCVS attacks in susceptible individuals, and targeting the angiotensin 2 receptor could be a preventive option.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147002PMC
http://dx.doi.org/10.3390/vaccines10050823DOI Listing

Publication Analysis

Top Keywords

rcvs attacks
12
covid-19 vaccine
12
reversible cerebral
8
cerebral vasoconstriction
8
vasoconstriction syndrome
8
pfizer covid-19
8
angiotensin receptor
8
attacks
5
rcvs
5
covid-19
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!